Drug Profile


Alternative Names: AEZS-130; ARD-07; D-87575; EP-01572; EP-1572; JMV-1843; Macimorelin acetate; Macrilen; Solorel

Latest Information Update: 04 Nov 2016

Price : $50

At a glance

  • Originator AEterna Zentaris Inc
  • Class Amides; Carboxylic acids; Indoles; Oligopeptides; Small molecules
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Somatotropin deficiency
  • Phase II Cachexia

Most Recent Events

  • 26 Oct 2016 Aeterna Zentaris completes enrolment in its phase III trial in Somatotropin deficiency (Diagnosis, In adults) in USA, Austria, France, Germany, Italy, Poland, Serbia, Spain, and the UK
  • 09 Aug 2016 AEterna Zentaris intends to resubmit an NDA application for Somatotropin deficiency (Diagnosis, In adults) in USA
  • 20 Nov 2015 Macimorelin is available for licensing as of 11 Nov 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top